OBJECTIVE: To assess changing patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms (PNENs). DESIGN: Retrospective review from May 21, 1977, through September 16, 2005. SETTING: Massachusetts General Hospital, a tertiary care center. PATIENTS: We evaluated 168 patients (51% male; mean age, 56 years) who underwent surgery for histologically confirmed PNENs. MAIN OUTCOME MEASURES: Surgical outcomes, survival, and changes in presentation of PNENs in 2 time groups: 1977-1999 (77 patients) and 2000-2005 (91 patients). RESULTS: Ninety-eight patients (58.3%) had nonfunctioning PNENs, 86 of which were incidental. Insulinomas were the most common type of functional neoplasm (33.3%), followed by gastrinomas and glucagonomas; 12 patients (7.1%) had multiple endocrine neoplasia type 1. Of the neoplasms, 107 (63.7%) were located in the pancreatic body or tail. A pancreaticoduodenectomy was performed in 37 patients (22.0%), distal pancreatectomy was done in 88 (52.4%), and the rest had either middle segment pancreatectomy or enucleation. There were no operative deaths. We classified 76.8% of neoplasms as benign; of those classified as malignant, 25.6% had liver metastases. Of the patients, 10.1% received adjuvant therapy. Complete follow up was available in 90.5% of patients (mean, 63.3 months). Five- and 10-year actuarial survival rates were 77% and 62%, respectively. Incidentally discovered nonfunctioning neoplasms were significantly more frequent in the last 5 years (60.4% vs 40.3%; P = .007), with a trend toward smaller neoplasms (mean, 4.2 cm vs 5.6 cm; P = .19) and lesser likelihood of malignancy (21.8% vs 40.0%; P = .08). CONCLUSIONS: We report a large single-center experience with PNENs. Increasing numbers of PNENs are being resected, largely owing to the incidental detection of nonfunctioning neoplasms. This may lead to the treatment of smaller and less malignant neoplasms.
OBJECTIVE: To assess changing patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms (PNENs). DESIGN: Retrospective review from May 21, 1977, through September 16, 2005. SETTING: Massachusetts General Hospital, a tertiary care center. PATIENTS: We evaluated 168 patients (51% male; mean age, 56 years) who underwent surgery for histologically confirmed PNENs. MAIN OUTCOME MEASURES: Surgical outcomes, survival, and changes in presentation of PNENs in 2 time groups: 1977-1999 (77 patients) and 2000-2005 (91 patients). RESULTS: Ninety-eight patients (58.3%) had nonfunctioning PNENs, 86 of which were incidental. Insulinomas were the most common type of functional neoplasm (33.3%), followed by gastrinomas and glucagonomas; 12 patients (7.1%) had multiple endocrine neoplasia type 1. Of the neoplasms, 107 (63.7%) were located in the pancreatic body or tail. A pancreaticoduodenectomy was performed in 37 patients (22.0%), distal pancreatectomy was done in 88 (52.4%), and the rest had either middle segment pancreatectomy or enucleation. There were no operative deaths. We classified 76.8% of neoplasms as benign; of those classified as malignant, 25.6% had liver metastases. Of the patients, 10.1% received adjuvant therapy. Complete follow up was available in 90.5% of patients (mean, 63.3 months). Five- and 10-year actuarial survival rates were 77% and 62%, respectively. Incidentally discovered nonfunctioning neoplasms were significantly more frequent in the last 5 years (60.4% vs 40.3%; P = .007), with a trend toward smaller neoplasms (mean, 4.2 cm vs 5.6 cm; P = .19) and lesser likelihood of malignancy (21.8% vs 40.0%; P = .08). CONCLUSIONS: We report a large single-center experience with PNENs. Increasing numbers of PNENs are being resected, largely owing to the incidental detection of nonfunctioning neoplasms. This may lead to the treatment of smaller and less malignant neoplasms.
Authors: Carlos Fernández-del Castillo; Javier Targarona; Sarah P Thayer; David W Rattner; William R Brugge; Andrew L Warshaw Journal: Arch Surg Date: 2003-04
Authors: C C Solorzano; J E Lee; P W Pisters; J N Vauthey; G D Ayers; M E Jean; R F Gagel; J A Ajani; R A Wolff; D B Evans Journal: Surgery Date: 2001-12 Impact factor: 3.982
Authors: Laura Rubbia-Brandt; Benoit Terris; Emile Giostra; Bertrand Dousset; Philippe Morel; Michael S Pepper Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: Timothy L Fitzgerald; Andrew J Smith; Max Ryan; Mostafa Atri; Frances C Wright; Calvin H L Law; Sherif S Hanna Journal: Can J Surg Date: 2003-12 Impact factor: 2.089
Authors: Vikram Deshpande; Carlos Fernandez-del Castillo; Alona Muzikansky; Anita Deshpande; Lawrence Zukerberg; Andrew L Warshaw; Gregory Y Lauwers Journal: Am J Surg Pathol Date: 2004-09 Impact factor: 6.394
Authors: Sean P Cleary; Robert Gryfe; Maha Guindi; Paul Greig; Lloyd Smith; Robert Mackenzie; Steven Strasberg; Sherif Hanna; Bryce Taylor; Bernard Langer; Steven Gallinger Journal: J Am Coll Surg Date: 2004-05 Impact factor: 6.113
Authors: Steven C Katz; Charan Donkor; Kristen Glasgow; Venu G Pillarisetty; Mithat Gönen; N Joseph Espat; David S Klimstra; Michael I D'Angelica; Peter J Allen; William Jarnagin; Ronald P Dematteo; Murray F Brennan; Laura H Tang Journal: HPB (Oxford) Date: 2010-12 Impact factor: 3.647
Authors: David J Worhunsky; Geoffrey W Krampitz; Peter D Poullos; Brendan C Visser; Pamela L Kunz; George A Fisher; Jeffrey A Norton; George A Poultsides Journal: HPB (Oxford) Date: 2013-08-29 Impact factor: 3.647
Authors: Satomi Kawamoto; Pamela T Johnson; Chanjuan Shi; Aatur D Singhi; Ralph H Hruban; Christopher L Wolfgang; Barish H Edil; Elliot K Fishman Journal: AJR Am J Roentgenol Date: 2013-03 Impact factor: 3.959
Authors: Timothy R Donahue; Kevork K Kazanjian; William H Isacoff; Howard A Reber; O Joe Hines Journal: J Gastrointest Surg Date: 2010-03-23 Impact factor: 3.452